# UTR Therapeutics

Source: https://onco.cc/companies/utr-therapeutics/  
OnCo record `utr-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

UTR Therapeutics is a New York company making RNA medicines that make a cancer-driving gene's message break down before it can be made into protein. Its sarcoma medicine, UTRxMYCN M1-14, aims at MYCN, a cancer gene that ordinary drugs cannot grip.

## Summary

UTR Therapeutics Inc., headquartered at 169 Madison Avenue in New York City, describes itself as an IND-stage company with an RNA overwriting platform delivered by an iron oxide nanocage, designed to downregulate a chosen transcript by engineering its 3' untranslated region so that the message is destroyed by nonsense-mediated decay. It reports preclinical work in c-MYC-driven and HER2-expressing tumours and says it has assets against c-MYC, MYCN, TEAD1, YAP1 and HER2; in May 2025 it announced an IND submission for a c-MYC programme. On 22 September 2026 the FDA granted orphan drug designation to UTRxMYCN M1-14 for soft tissue sarcoma, including rhabdomyosarcoma, and the company announced a Rare Pediatric Disease Designation for rhabdomyosarcoma at the same time.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: UTR Therapeutics Inc.; UTRx Inc.
- HQ: New York, NY
- Type: biotech
- Website: https://www.utrtherapeutics.com/

## Notes

- Read on the company website (a single-page application whose text was read from its published script) on 4 November 2026. The efficacy claims for UTRxMYCN M1-14 are preclinical and the company's own. No technology record fits 3' UTR overwriting exactly; antisense-sirna is the nearest RNA-targeting entry.

## Sources

- Official website: https://www.utrtherapeutics.com/
- FDA orphan designation, soft tissue sarcoma, 22 September 2026: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1182626

## Connected records

- cancers: [Rhabdomyosarcoma](https://onco.cc/cancers/rhabdomyosarcoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Oligonucleotide therapeutics](https://onco.cc/technologies/antisense-sirna/)
- targets: [MYCN (N-myc)](https://onco.cc/targets/mycn/)
- drugs: [UTRxMYCN M1-14](https://onco.cc/drugs/utrxmycn-m1-14/)

---
JSON: https://onco.cc/api/v1/entities/utr-therapeutics.json